The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
OkamotoI.YamamotoN.KubotaK.Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer. Invest New Drugs.2012; 30(3): 1132–1137.
2.
SatouchiM.OkamotoI.SakaiH.Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer.2013; 81(1): 97–101.
3.
SocinskiM.A.LangerC.J.OkamotoI.Safety and efficacy of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol.2013; 24(2): 314–321.
4.
SocinskiM.A.ManikhasG.M.StroyakovskyD.L.A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol.2010; 5(6): 852–861.
5.
SocinskiM.A.BondarenkoI.KarasevaN.A.Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol.2012; 30(17): 2055–2062.
6.
SocinskiM.A.OkamotoI.HonJ.K.Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. Ann Oncol.2013; 24(9): 2390–2396.
7.
NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer. V.3.2014. National Comprehensive Cancer Network Web site. www.nccn.org. Accessed March 13, 2014.
8.
CalvertA.H.NewellD.R.GumbrellL.A.Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol.1989; 7(11): 1748–1756.
9.
CockcroftD.W.GaultM.H.Prediction of creatinine clearance from serum creatinine. Nephron.1976; 16(1): 31–41.
10.
CathomasR.HarleA.MeadG.M.Glomerular filtration rate (GFR) in patients with stage I testicular seminoma treated with adjuvant carboplatin: A comparison of six formulae compared to a radioisotope gold standard. J Clin Oncol.2007; 25(18 Suppl): abstract 15504.
11.
BoumedienF.ArsenaultY.LeTarteN.Impact of weight and creatinine measurements in carboplatin dosing. J Clin Oncol.2012; 30(15 Suppl): abstract e13027.
12.
EkhartC.RodenhuisS.SchellensJ.H.M.BeijnenJ.H.HuitemaA.D.R.Carboplatin dosing in overweight and obese patients with normal renal function. Does weight matter?Cancer Chemother Pharmacol.2009; 64(1): 115–122.
13.
HerringtonJ.D.TranH.T.RiggsM.W.Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥ 27 or cachexia. Cancer Chemother Pharmacol.2006; 57(2): 241–247.
14.
DevineB.J.Gentamycin therapy. Drug Intell Clin Pharm.1974; 8: 650–655.
15.
KaagD.Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors. Lung Cancer.2013; 79(1): 54–58.
16.
HerringtonJ.D.TranH.T.RiggsM.W.Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥ 27 or cachexia. Cancer Chemother Pharmacol.2006; 57(2): 241–247.
17.
O'CearbhaillR.New guidelines for carboplatin dosing. Gyn Oncol Group Newsletter.2012; (Spring issue): 5–6.
CheungY.W.CradockJ.C.VishnuvajjalaB.R.FloraK.P.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm.1987; 44(1): 124–130.
20.
PaikP.JamesL.RielyG.A phase II study of weekly albumin-bound paclitaxel (Abraxane) given as a two-hour infusion. Cancer Chemother Pharmacol.2011; 68(5): 1331–1337.
21.
NCCN Clinical Practice Guidelines in Oncology for Antiemesis. V.1.2014. National Comprehensive Cancer Network Web site. www.nccn.org. Accessed March 13, 2014.
Multinational Association of Supportive Care in Cancer. MASCC/ESMO Antiemetic Guidelines 2013. Multinational Association of Supportive Care in Cancer Web site. http://www.mascc.org/antiemetic-guidelines. Accessed January 21, 2014.
24.
GelingO.EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
